Carbon monoxide-releasing molecules for therapeutic applications and methods for the preparation and use thereof

US10751344B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10751344-B2
Application numberUS-201916423094-A
CountryUS
Kind codeB2
Filing dateMay 27, 2019
Priority dateJun 9, 2014
Publication dateAug 25, 2020
Grant dateAug 25, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for therapeutic applications in vivo, the cycloaddition and CO release typically occur only under near-physiological or physiological conditions. For example, in some embodiments, the cycloaddition reaction and/or release of carbon monoxide occur at a temperature of about 37° C. and pH of about 7.4. Pharmaceutical compositions and methods for release carbon monoxide are also described.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound according to Formula IX: or a pharmaceutically acceptable salt thereof, wherein: R 1 and R 2 are phenyl, each of which is optionally substituted with one or more R 11 moieties, or R 1 and R 2 are phenyl and are taken together to form a fused tricyclic moiety which is optionally substituted with one or more R 11 moieties, wherein R 3 is selected from the group consisting of cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; each R 4 and R 5 is independently selected from the group consisting of hydrogen, substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, a protecting moiety R P , a linking moiety R L , a targeting moiety R T , and a solubility-enhancing moiety R S ; R 6 is independently selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, a protecting moiety R P , a linking moiety R L , a targeting moiety R T , and a solubility-enhancing moiety R S ; each R 11 is independently selected from the group consisting of halogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, alkoxy, aryloxy, hydroxyl, —N(R a ) 2 , —SR a , —S(O)R a , —S(O) 2 R a , —OS(O)OR a , —OS(O) 2 OR a , —OP(OR a ) 2 , —OP(O)HOR a , —OP(OR a ) 2 , —OP(O)(R a ) 2 , —P(O)(OR a ) 2 , —ONO, —ONO 2 , —NO 2 , —(C═O)R 5 , —(C═O)OR 6 , —(C═O)NR 7 R 8 , a linking moiety R L , a targeting moiety R T , and a solubility-enhancing moiety R S ; R a is selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl, and heteroaryl; each R 7 , R 8 , R 9 , and R 10 is independently selected from the group consisting of hydrogen, alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl; X is NR 14 wherein R 14 is hydrogen or alkyl, which is optionally substituted with halogen, haloalkyl, haloalkoxy, —OR′, or —NR′R″, R′ and R″ are independently selected from the group consisting of hydrogen and unsubstituted alkyl; or R′ and R″, when attached to the same nitrogen atom, are combined with the nitrogen to which they are attached to form heterocycloalkyl or heteroaryl; each R 15 is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocycloalkyl, alkenyl, alkynyl, aryl, and heteroaryl, or, alternatively two OR′ are taken together to form an oxo moiety; and subscript n is 1, 2 or 3. 2. The compound of claim 1 , wherein R 4 and R 5 are hydrogen. 3. The compound of claim 2 , wherein subscript n is 1 or 2. 4. The compound of claim 1 , wherein X is NR 14 and R 14 is selected from the group consisting of hydrogen, alkyl, and heteroalkyl. 5. The compound of claim 4 , wherein R 4 and R 5 are hydrogen. 6. The compound of claim 5 , wherein subscript n is 1 or 2. 7. A method for generating carbon monoxide in vivo or ex vivo, the method comprising: allowing a precursor molecule according to claim 1 to react to form an organic molecule that releases carbon monoxide under physiological conditions. 8. The method of claim 7 , wherein the carbon monoxide is released in an amount effective for the treatment of inflammation, cardiovascular disease, cancer, sepsis, or a combination thereof. 9. The method of claim 8 , wherein R 4 and R 5 are hydrogen. 10. The method of claim 9 , wherein subscript n is 1 or 2. 11. The method of claim 8 , wherein X is NR 14 and R 14 is selected from the group consisting of hydrogen, alkyl, and heteroalkyl. 12. The method of claim 11 , wherein R 4 and R 5 are hydrogen. 13. The method of claim 12 , wherein subscript n is 1 or 2. 14. A method for treating inflammation, cardiovascular disease, cancer, sepsis, or a combination thereof, the method comprising administering an effective amount of a compound according to claim 1 to a subject in need thereof. 15. The method of claim 14 , wherein R 4 and R 5 are hydrogen. 16. The method of claim 15 , wherein subscript n is 1 or 2. 17. The method of claim 14 , wherein X is NR 14 and R 14 is selected from the group consisting of hydrogen, alkyl, and heteroalkyl. 18. The method of claim 17 , wherein R 4 and R 5 are hydrogen. 19. The method of claim 18 , wherein subscript n is 1 or 2. 20. The method of claim 14 , wherein the compound is administered parenterally.

Assignees

Inventors

Classifications

  • Diels-Alder reactions · CPC title

  • Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

  • of acids having aromatic rings, e.g. benactizyne, clofibrate · CPC title

  • A61K31/122Primary

    having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title

  • carbocyclic · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10751344B2 cover?
Carbon monoxide-releasing organic molecules are described herein. The molecules can be synthesized prior to administration (e.g., ex vivo) or formed in vivo. In those embodiments where the molecules are formed in vivo, reactants are administered under physiological conditions and undergo a cycloaddition reaction to form a product which releases carbon monoxide. In applying such reactions for th…
Who is the assignee on this patent?
Univ Georgia State Res Found
What technology area does this patent fall under?
Primary CPC classification A61K31/122. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).